A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.
Multiple Myeloma
DRUG: SHR-9539 for injection
RP2D of SHR-9539 injection, Determination of the recommended phase 2 dose (RP2D) of SHR-9539 injection in patient with multiple myeloma., Approximately 24 months
Incidence and severity of AE, Assessing the incidence of adverse events (AEs) mainly using the Common Terminology Criteria for Adverse Events (CTCAE Version 5), and CRS and ICANS were graded according to ASTCT standards., Up to follow-up period, approximately 24 months|Cmax, Maximum serum concentration, Up to follow-up period, approximately 24 months|Tmax, Time to reach maximum plasma concentration., Up to follow-up period, approximately 24 months|Overall Response Rate (ORR), ORR assessed by the IMWG response criteria., Up to follow-up period, approximately 24 months
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.